CYTODYN INC (CYDY) analyst actions
Rating and price-target actions on CYDY in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CYDY overview →
2 measured CYDY analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer | Press release | -0.92% | -5.03% | |
| CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma | Press release | +0.97% | +2.34% |
Keep exploring
More CYDY: earnings → · SEC filings → · CYDY overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Arbutus Biopharma Corporation (ABUS) | 191 | +0.11% | 52% |
| BeiGene, Ltd. - American Depositary Shares (BGNE) | 191 | +0.11% | 52% |
| BAVARIAN NORDIC R/I S/ADR (BVNRY) | 190 | 0.00% | 29% |
| U S STEM CELL INC (USRM) | 190 | 0.00% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.